Loading InvisibleSignal...

Research Insights

Evidence synthesis across invisible illness research, highlighting funding disparities, publication trends, biomarker discovery, and clinical trial activity for Lyme disease, Long COVID, ME/CFS, Fibromyalgia, POTS, and Alpha-gal Syndrome.

Diagnostic Odyssey

4.5 years

Average time to diagnosis across conditions, with patients seeing 8+ providers before receiving an accurate diagnosis.

Economic Impact

$24.6B / year

Annual economic burden across invisible illnesses, with 67% attributed to lost productivity and workforce non-participation.

Comorbidity Burden

73% overlap

Of patients have 2+ overlapping conditions, complicating diagnosis, treatment, and insurance coverage.

Research Gap Analysis

NIH funding per patient (USD) reveals stark disparities across conditions.

Publication Trends

Research publications indexed in PubMed/MEDLINE by condition (2018 - 2025).

Biomarker Discovery Pipeline

Potential biomarkers under active investigation across invisible illness research programs.

Cytokine Panels

Phase II Validation

IL-6, TNF-alpha, IFN-gamma multiplex panels showing differential expression across post-infectious syndromes.

LymeLong COVIDME/CFS

Autoantibodies

Discovery

Anti-adrenergic and anti-muscarinic receptor autoantibodies linked to autonomic dysfunction.

POTSLong COVIDME/CFS

Microbiome Signatures

Phase I

Gut microbiome depletion patterns correlating with symptom severity and treatment response.

LymeFibromyalgiaAlpha-gal

Neuroimaging Patterns

Discovery

fMRI and PET-CT revealing neuroinflammation patterns in brainstem and basal ganglia.

ME/CFSFibromyalgiaLong COVID

Metabolomics

Phase I

Altered tryptophan-kynurenine pathway metabolites and mitochondrial dysfunction markers.

ME/CFSLymePOTS

Clinical Trial Landscape

Active clinical trials by average sample size, duration, and trial count per condition.

Lyme (42 trials)Long COVID (128 trials)ME/CFS (23 trials)Fibromyalgia (56 trials)POTS (18 trials)Alpha-gal (8 trials)

Explore Related Modules

Pattern Engine

Cross-condition analysis

Demographics

Prevalence disparities

Compare Conditions

Side-by-side condition analysis

National Dashboard

Aggregate economic burden

Data Sources (4)

National Institutes of Health. NIH RePORTER Funding Database. 2024.
National Library of Medicine. PubMed/MEDLINE Publication Database. 2024.
U.S. National Library of Medicine. ClinicalTrials.gov Registry. 2024.
Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. 2023.

Research Insights

Diagnostic Odyssey

4.5 years

Average time to diagnosis across conditions, with patients seeing 8+ providers before receiving an accurate diagnosis.

Economic Impact

$24.6B / year

Annual economic burden across invisible illnesses, with 67% attributed to lost productivity and workforce non-participation.

Comorbidity Burden

73% overlap

Of patients have 2+ overlapping conditions, complicating diagnosis, treatment, and insurance coverage.

Research Gap Analysis

NIH funding per patient (USD) reveals stark disparities across conditions.

Publication Trends

Research publications indexed in PubMed/MEDLINE by condition (2018 - 2025).

Biomarker Discovery Pipeline

Potential biomarkers under active investigation across invisible illness research programs.

Cytokine Panels

Phase II Validation

IL-6, TNF-alpha, IFN-gamma multiplex panels showing differential expression across post-infectious syndromes.

LymeLong COVIDME/CFS

Autoantibodies

Discovery

Anti-adrenergic and anti-muscarinic receptor autoantibodies linked to autonomic dysfunction.

POTSLong COVIDME/CFS

Microbiome Signatures

Phase I

Gut microbiome depletion patterns correlating with symptom severity and treatment response.

LymeFibromyalgiaAlpha-gal

Neuroimaging Patterns

Discovery

fMRI and PET-CT revealing neuroinflammation patterns in brainstem and basal ganglia.

ME/CFSFibromyalgiaLong COVID

Metabolomics

Phase I

Altered tryptophan-kynurenine pathway metabolites and mitochondrial dysfunction markers.

ME/CFSLymePOTS

Clinical Trial Landscape

Active clinical trials by average sample size, duration, and trial count per condition.

Lyme (42 trials)Long COVID (128 trials)ME/CFS (23 trials)Fibromyalgia (56 trials)POTS (18 trials)Alpha-gal (8 trials)

Explore Related Modules

Pattern Engine

Cross-condition analysis

Demographics

Prevalence disparities

Compare Conditions

Side-by-side condition analysis

National Dashboard

Aggregate economic burden

Data Sources (4)

National Institutes of Health. NIH RePORTER Funding Database. 2024.
National Library of Medicine. PubMed/MEDLINE Publication Database. 2024.
U.S. National Library of Medicine. ClinicalTrials.gov Registry. 2024.
Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. 2023.